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A B S T R A C T
Since diabetes tends to progressively worsen over time, glycemic control often deteriorates in spite of taking regular
therapy. Therefore, numerous research studies are by and large focused on finding more efficient therapy, both new medi-
cines for treating type 2 diabetes mellitus, as well as supplements that could serve as an addition to conventional treat-
ment modalities. A variety of herbal preparations have been shown to have modest short-term beneficial effects on glyce-
mia, but of these, the best studied is American ginseng (AG). AG has been shown to be effective in improving glycemic
control in type 2 diabetes through increasing post-prandial insulin levels and decreasing postprandial glycemic respon-
se. However, high variability in ginsenosides may result in just as high variability in antidiabetic efficacy of over-the-
-counter ginseng products. Therefore, the availability of standardized extracts of AG could assist greatly in advancing
our knowledge on the role of this traditionally used herb and result in a wider application of ginseng product in diabetes
management. The aim of this review is to outline the efficacy and safety of American ginseng for AG preparations on
glycemic control in patients with type 2 diabetes as well as to increase awareness of the evidence supporting the use of
these therapies in diabetes care.
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Introduction
A growing worldwide epidemic of diabetes combined
with the frequent failure of primary drug treatment in
the majority of patients, make a compelling argument for
better prevention and treatment strategies. Between
1995 and 2025 there will be a 35% increase in the world-
wide prevalence of diabetes with a higher rise in devel-
oped than in developing countries1. The number of adults
with diabetes in the world is estimated to increase by
122%, from 135 to 300 million1. Since glycemic control
tends to worsen over time and additional medications are
required to maintain the status quo, new, safe and effec-
tive treatments are of interest. Numerous research stud-
ies are by and large focused on finding more efficient
therapy, both new medicines for treating type 2 diabetes
mellitus, as well as supplements that could serve as an
addition to conventional treatment modalities. Comple-
mentary and alternative medicine (CAM) use has in-
creased at a considerable pace in recent years among the
general public2. In 2007, almost 4 out of 10 adults in the
U.S. had used CAM therapy in the past 12 months, with
the most commonly used therapies being nonvitamin,
nonmineral, natural products (17.7%) and deep breath-
ing exercises (12.7%)2. One of the surveys that examined
CAM use among those with diabetes reported that about
one third of respondents use CAM to treat their con-
dition3, whereas another national survey in the US re-
ported a lower incidence (8%) of diabetic patients using
CAM4. Generally, data for the therapeutic effectiveness
and safety of herbal products are lacking5. Nevertheless,
herbal remedies or other dietary supplements taken by
mouth are among the most prevalent CAM3,4, and have
been increasingly used in treatment of type 2 diabetes5.
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Among 36 examined herbs the most promising supple-
ments with purported hypoglycemic activity include Ivy
gourd (Coccinia indica), American ginseng (Panax spp.),
Bitter Melon (Momordica charantia), Gurmar (Gymne-
ma sylvestre), Aloe vera, nopal, L-carnitine and vana-
dium5. American ginseng (Panax quinquefolius L.) along
with Ivy gourd were found to have the best evidence from
adequately designed randomized controlled trials (RCTs)
to support clinical efficacy in diabetes5. A review by the
American Diabetes Association in their 2002 Evidence
Based Nutrition Recommendations has concluded that a
variety of herbal preparations have been shown to have
modest short-term beneficial effects on glycemia, but of
these, the best studied is American ginseng6. The aim of
this review is to outline the efficacy and safety of Ameri-
can ginseng preparations on glycemic control in patients
with type 2 diabetes as well as to increase awareness of
the evidence supporting the use of these therapies in dia-
betes care.
Ginseng – Background
Ginseng is a slow-growing herbaceous perennial be-
longing to the plant family Araliaceae and genus Panax
indigenous both to Asia and North America. Thirteen
distinct species of ginseng have been identified with nu-
merous different cultivars7. These include Chinese or
Korean ginseng (Panax ginseng C.A. Meyer), American
ginseng (P. quinquefolius L.), Japanese ginseng (P. japo-
nicus), Sanchi, and Vietnamese (P. vietnamensis). Two of
the most common types are Panax quinquefolius L. and
Panax ginseng C.A. Meyer, more commonly referred to as
American ginseng and Asian ginseng8. Both have compa-
rable compositions, but could be considered to be differ-
ent in their effect. Asian ginseng and some of its frac-
tions have been traditionally used as a sedative, tonic,
anti-fatigue, anti-gastric ulcer drug, and also thought to
have antitumor, memory increasing and immunostimu-
lation activities9. Based on in vitro and animal research
findings American ginseng, cultivated in United States
and Canada, is thought to reduce stress, lower high blood
sugar, increase sex drive, memory and learning abilities,
decrease aging and adjust immunity10.
Chemical Composition – Ginsenoside
It is believed that the primary active components of
ginseng to which pharmacological effects have been at-
tributed are a group of >30 different triterpene sapo-
nins, also refered to as ginsenosides, which vary in con-
tent and relative proportions among different species of
ginseng9,11. Its other components that have also demon-
strated pharmacological activity to some extent include
polysaccharide (ginsenans)12,13 and peptide (panaxans/
quinquefolans/eleutherans) fractions11.
Differences in ginsenoside content have been obser-
ved between wild kinds and its cultivated counterpart14,
ginseng harvested from different locations, within the
same plant15, among root parts16, and according to its age
(largest increases coming between 4th and 6th years of
growth)17. Both these interspecies and intraspecies dif-
ferences contribute to a high degree of variability of
ginsenosides implying that the effects of ginseng could be
equally highly variable in its pharmacological effect which
is often reflected in commercial ginseng products18. Poor
standardization of ginsenosides remains a major barrier
to its efficacy and safety18,19.
Mechanism of Hypoglycemic
Activity of Ginseng
Mechanisms of action of different ginseng sources and
components through which glycemic control is achieved
are not fully clear. Studies have shown that ginseng and
its components could influence hyperglycemia through
enhancing pancreatic b-cell function and through reduc-
ing insulin resistance. Four possible mecahnisms of ac-
tion that have been proposed include glucose absorption,
insulin secretion and binding, glucose transport, and/or
glucose disposal. Indirect evidence suggest that different
sources of ginseng may affect the rate of digestion which
results in decreasing rate of carbohydrate absorption in-
to portal hepatic circulation20. Various ginseng extracts,
ginsenosides and panaxan B increase insulin secretion
and binding, as seen in many studies21–23 by stimulating
insulin biosynthesis21, increasing glucose22 and nonglu-
cose stimulated insulin secretion, and increasing insulin
binding23. Glucose transport in various cell lines may
also be increased by increasing proteins responsible for
transport in a dose dependent manner24. It has been
found that glucose disposal may be increased by different
ginseng extracts and ginsenosides through increasing ac-
tivity of several enzymes25 or decreasing activity of the
rate limiting gluconeogenic enzyme glucose-6-phospha-
tase26. American ginseng has been shown to be effective
in improving glycemic control in type 2 diabetes through
increasing post-prandial insulin levels, achieved via al-
tering cell metabolism, increasing insulin production and
reducing apoptosis in a dosage dependent manner27. The
action of AG could be compared to sulphonylurea, which
has an insulinotropic effect on pancreatic b-cells. The dif-
ference between ginseng and sulphonylurea, however, is
that ginseng only stimulates insulin release in response
to a meal (i.e. a glucose-stimulated insulin secretion)10.
The advantage of taking AG is thus a reduced risk of
hypoglycemic episodes in the case of postponed or missed
meals, a common issue for patients on sulphonylurea
treatment. This was also demonstrated in an 8-week study
where no hypoglycaemic episodes were recorded despite
having added American ginseng to current treatments28.
Hypoglycemic Activity – Preclinical
and Clinical Evidence
Though recent systematic reviews5,8 remarked on the
lack of sound proof to make conclusions about the effi-
cacy of ginseng, numerous reports that have emphasized
anti-hyperglycemic effect of ginseng have begun emerg-
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ing in human as well as animal studies. Animal studies
have demonstrated significant anti-hyperglycemic action
by a variety of ginsengs (e.g. American, Chinese, Siberian
and Korean Red) using either the root or a particular ex-
tract of the root29. In one animal study, methanol fraction
extract of AG, ferulic acid, and cinnamic acid yielded
antihyperglycemic effects in a type 2 diabetic mouse
model30. In addition, the glycogen and high density lipo-
protein (HDL) contents were significantly increased whi-
le levels of plasma cholesterol and low density lipoprotein
(LDL) concentration were significantly decreased in the
AG treated group30. Intraperitoneal injections of TGCG
(total ginsenosides in Chinese ginseng) or oral adminis-
tration for 12 days significantly lowered the fasting blood
glucose levels in diabetic ob/ob mouse model which indi-
cated TGCGwas endowed with significant anti-hypergly-
cemic properties31. Ginsenoside Re reduced blood glucose
levels, improved levels of cholesterol and triglycerides as
well as reduced oxidative stress in diabetic rats29. Based
on animal studies, it has been suggested that ginseng in-
creases insulin secretion, insulin sensitivity and may
slow gastric emptying. Ginseng might mediate the insu-
lin stimulated glucose uptake in rat skeletal muscles and
adipose tissue32 as well as glucose dependent secretion of
insulin in rat islet cells33.
Clinical studies have also reported that American gin-
seng has the ability to lower blood glucose in diabetic pa-
tients. To select batches and treatment protocols (dosing,
timing, and modes of administration) of American gin-
seng (Chai-Na-Ta Corp., BC, Canada) that achieve repro-
ducible and sustainable efficacy, a series of five acute,
randomized, single-blind, placebo-controlled clinical stu-
dies were conducted in subjects with and without diabe-
tes using a 25 g OGTT protocol. It was found that Ameri-
can ginseng reduced postprandial glycemia from 9.1–
38.5% when administered either 30–40 min before, or to-
gether, with an oral glucose challenge in subjects with di-
abetes, and only when given 30–40 min before the chal-
lenge in normal subjects10. Doses from 1–9 g were equally
efficacious and time from 0–120 min before the glucose
challenge was equally efficacious in diabetic subjects
without interaction with their background antihyper-
glycemic therapy10,34,35. It was also found that adminis-
tration of 6g of AG increased the insulin secretion twofold
in the first 45 min after a 25 g oral glucose challenge19.
As the first 60 min of a 25 g oral glucose challenge is con-
sidered to be representative of the early phase of insulin
secretion, these data suggest that AG may be able to af-
fect this phase, the loss of which is a primary defect in
type 2 diabetes. Although it was tempting to suggest that
its ginsenoside composition was responsible for these ef-
fects, other unmeasured components, such as unmea-
sured ginsenosides, peptidoglycans, various ginsenans,
peptides, fatty acids and other organic compounds could
have played an independent or interactive role. It was
concluded that the ginsenoside profile was interpretable
only for authentication10,34,35, and replication of the find-
ings with an American ginseng selected or designed to
have a similar profile was considered the most reason-
able approach.
Until recently, there was a limited amount of long-
-term clinical studies that could support the use of gin-
seng in treatment of diabetic patients. Sotaniemi and co-
workers reported that 8 weeks of treatment with 100 mg
or 200 mg/day of an unspecified ginseng extract im-
proved fasting glycemia and long-term glycemic control,
assessed by HbA1c36. However, due to significant weight
loss differences between the treatment groups and weak-
ly described statistics results were equivocal. Another
study, that investigated the long-term therapeutic value
of American ginseng, used an American ginseng extract
with a ginsenoside profile similar to the one used in the
series of 5 acute studies10,34,35. In an 8-week double-blind,
placebo-controlled crossover trial, in which the American
ginseng extract (Chai-Na-Ta Corp., BC, Canada) or corn
starch placebo at a dose of 1 g was taken 40 min before
each meal (3 g/day), it was found that fasting glucose and
HbA1c were decreased compared with placebo after 8
weeks28. There was also an observable but insignificant
increase in insulin suggesting a possible improvement in
b-cell function. These benefits occurred without increas-
ing adverse events or altering hepatic, renal, haemo-
static, or blood pressure function.
Due to a lack of clear distinction between various gin-
seng species, remarks made about its alleged hypoglyce-
mic effect and evidence from sound clinical trials did not
support the use of ginseng in alleviating hyperglycemia8.
This limitation is particularly true for ginseng, and the
fact that these prominent species (Panax ginseng and
Panax quinquefolium) distinguish themselves signifi-
cantly in terms of their complex mixture of numerous po-
tentially bioactive constituents (e.g. ginsenosides). Most
of ginseng’s components have not yet had their effects
reproduced, while in some other cases effects have been
both hypoglycemic and hyperglycemic for the same com-
ponent between different studies23,37 which could be at-
tributed to the differences in models studied.
Cardioprotective Effects of
American Ginseng
Various sources of AG showed differential effects on
different metabolic disorders related to diabetes in vari-
ous human cohorts, such as dyslipidemia, hypertension,
obesity and impaired fibrinoloysis. In a longterm, ran-
domized, double-blind, crossover study the selected AG
extract given at a dose of 1 g as an oral agent – 40 min
preprandially TID (3 g/day), decreased total-cholesterol,
LDL-cholesterol, and the Total-/HDL-cholesterol ratio
compared with placebo, with an observable but insignifi-
cant increase in HDL cholesterol in subjects with type 2
diabetes38. Similar results were reported in a longterm,
randomized, double-blind, crossover study investigating
the efficacy and safety of the combination of the selected
batch of AG plus viscous soluble-fiber blend containing
Konjac mannan, where after 12-weeks of therapy combi-
nation treatment reduced total cholesterol by 7%, LDL
cholesterol by 10%, and apolipoprotein B100 (apoB100)
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by 9.9% compared to placebo in 30 subjects with well-
-controlled type 2 diabetes39.
Compared to other ginseng species (e.g. Korean red
ginseng), AG has shown less consistent effects on blood
pressure. Eight weeks of supplementation with the se-
lected AG extract given at a dose of 1g as an oral agent –
40 min preprandially TID (6g/day) significantly reduced
systolic and diastolic blood pressures compared with pla-
cebo in 24 subjects with type 2 diabetes40. In contrast,
two follow up studies showed neutral acute and long-
-term effects of 6 batches of AG41,42. Moreover, it was con-
cluded that long-term ginseng use had a neutral effect on
renal function in hypertensive individuals42. Based on
this, it can be said that American ginseng is safe for use
by individuals who have hypertension.
In addition, systematic review of the effects of ginseng
on cardiovascular risk factors yielded incosistent re-
sults43. They found that ginseng slightly decreased blood
pressure compared with placebo (range 0–4%), with 5 of
9 studies showing improvement in one or more lipid pa-
rameters compared with baseline (range 7–44%)43. No
changes in weight were reported with the selected AG ex-
tract in any of the afore mentioned studies19,28,39,42. Im-
provements in haemostatic parameters have been ob-
served with an AG extract where a significant reduction
in plasminogen activator inhihibitor-1 (PAI-1) was ob-
served from week 0 to week 12 in 24 type 2 diabetic
subjects44.
Furthermore, effects of North American ginseng, re-
ported to reduce cardiac hypertrophy, were investigated
on RhoA/ROCK (Ras homolog gene family, member A/
Rho-associated, coiled-coil containing protein kinase) and
mitogen-activated protein kinase (MAPK) activation in
ventricular cardiomyocytes exposed to leptin (50 ng/mL)
and the possible role of p115RhoGEF and p63RhoGEF in
these responses45. Results of the study demonstrated a
potent inhibitory effect of ginseng against leptin-induced
cardiac hypertrophy, an effect associated with prevention
of p115RhoGEF-RhoA/ROCK-dependent p38 MAPK ac-
tivation45. The effects of AG and heat-processed AG (H-AG)
on diabetic renal damage using streptozotocin (STZ)-in-
duced diabetic rats were investigated46. The study found
that AG and H-AG inhibit advanced glycation endpro-
duct (AGE) acumulation in diabetic rat kidney by their
hypoglycemic and renal function ameliorating effects, and
this effect was stronger in the H-AG-administered group
than in the AG-administered group. These findings indi-
cate that H-AG may have beneficial effect on pathologi-
cal conditions associated with diabetic nephropathy46.
Recent studies have revealed that ginseng, including
AG, exerts antioxidant effects in the cardiovascular sys-
tem; however, the underlying mechanisms are not fully
understood47. One of the proposed mechanisms was that
AG suppresses oxidative stress and oxidative stress-in-
duced cell death in cardiomyocytes through activating
the Nrf2 pathway, thereby providing cardioprotection
against pathological cardiac remodeling47. Another study
suggested that ginsenoside Rb1 (gRb1) conferred cardio-
protection that was mediated via attenuating reactive
oxygen species (ROS) and suppressing ROS-induced
JNK activation48.
These data suggest that American ginseng might play
complementary roles in reducing diabetes and cardiovas-
cular disease risk in humans. However, despite some evi-
dence showing beneficial effects on cardiovascular risk
factors, well-designed, randomized, controlled trials eval-
uating its effects are lacking.
Safety
Although ginseng employment has not been associ-
ated with reports related to its toxicity, various side-ef-
fects have been associated to its use49. Several adverse ef-
fects include insomnia, diarrhea, vaginal bleeding,
mastalgia, severe headache, schizophrenia, and the Ste-
vens-Johnson syndrome8. However, their incidence seems
to be low. When taken at doses much higer than the rec-
ommended dose, up to 15 g per day, for a 2 year period,
around 10% of patients in an observational study re-
ported hypertension, gastrointestinal disturbances, in-
somnia and nervousness. The validity of these side-ef-
fects is questionable due to a lack of placebo treatment in
the study and the fact that subjects were not controlled
for other bioactive substance intake (e.g. caffeine)50. Only
a few cases of ginseng toxicity or side-effects were re-
ported when taken at the recommended dosages.
Results of a randomized, double-blind, placebo-con-
trolled study of efficacy and safety revealed that ginseng
use did not appear to compromise safety51. Overall, study
showed no differences between the intervention and the
control groups in frequency and severity of adverse
events28. To support what was previously stated, results
of a 2002 systematic review of 146 clinical trials with gin-
seng reported that the incidence of adverse events in in-
tervention and control groups was similar52. Ginseng use
was found to be well tolerated and its effects mild and re-
versible. Though ginseng has been proclaimed as without
contraindications and serious adverse effects53, use of
CAM in general has not been approved in the treatment
of diabetes on the basis of inadequate evidence for its
safety and efficacy.
Recommendations
A 2003 systematic review of 42 randomized and 16
nonrandomized clinical trials showed that AG along with
Ivy gourd have the best evidence from adequately de-
signed RCTs to support clinical efficacy in diabetes7. A
review by the American Diabetes Association in their
2002 evidence based nutrition recommendations drew
the same conclusion related to AG10.
Conclusion
Diabetes is possibly the world’s fastest growing meta-
bolic disorder, and as the awareness of the need for
tighter glycemic control increases, so does the need for
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more appropriate therapies54–57. Both clinical and animal
studies have indicated that ginseng root has the ability to
improve glycemic control, and that it might serve as a
simple dietary adjunct to existing therapies. Despite hav-
ing the best evidence for efficacy in diabetes among
herbs, the evidence remains inconclusive for ginseng.
This owes both to the insufficiency in data quantity and
quality, and a lack of reproducibility of its safety and effi-
cacy. Furthermore, high variability in ginsenosides may
result in just as high variability in antidiabetic efficacy
and safety of different batches, and as such, may not be
generalizable to over-the-counter ginseng products. Poor
standardization of ginseng calls for a more direct and
systematic clinical approach to identify active compo-
nents what would generate reproducible and sustainable
clinical evidence and result in a wider ginseng product
use. Nevertheless, since AG has been shown to be effective
in improving glycemic control in type 2 diabetes (through
increasing post-prandial insulin levels), if further re-
search reaffirms its safety and efficacy this new therapy
could provide a useful addition to conventional treat-
ments. Therefore, the availability of standardized ex-
tracts of American ginseng will assist greatly in advanc-
ing our knowledge on the role of this traditionally used
herb and move industry toward a better understanding
of which processing method to use in order to preserve
the efficacy of AG.
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UTJECAJ AMERI^KOG GINSENGA (Panax quinquefolius L.) NA KONTROLU GLIKEMIJE
U [E]ERNOJ BOLESTI TIPA 2
S A @ E T A K
S obzirom na progresivni tijek {e}erne bolesti, regulacija glikemije se usprkos redovitom uzimanju terapije ~esto
pogor{ava. Stoga su brojna istra`ivanja usmjerena na pronala`enje u~inkovitije terapije, i to kako na nove lijekove za
lije~enje {e}erne bolesti tako i na primjenu dodataka u prehrani koji bi mogli biti korisna dopuna konvencionalnoj
terapiji. Razli~iti biljni pripravci pokazali su umjerene i kratkotrajne povoljne u~inke na glikemiju, ali od svih je najvi{e
istra`ivan ameri~ki ginseng (AG). AG se pokazao djelotvornim u pobolj{anju regulacije glikemije kod {e}erne bolesti
tipa 2 kroz pove}anje post-prandijalne razine inzulina i smanjenje post-prandijalnog glikemijskog odgovora. Me|utim,
visoka varijabilnost ginsenozida mogla bi rezultirati jednako visokom varijabilno{}u antidijabeti~kog u~inka over-the-
-counter (OTC) pripravaka ginsenga. Stoga bi raspolo`ivost standardiziranih ekstrakata AG-a mogla uvelike pomo}i u
unaprje|enju na{eg znanja o ulozi ove tradicionalno kori{tene biljke, te rezultirati {irim kori{tenjem pripravaka gin-
senga u terapiji {e}erne bolesti. Cilj ovog pregleda je istaknuti u~inkovitost i sigurnost preparata AG-a u regulaciji
glikemije kod pacijenata s tipom 2 {e}erne bolesti, kao i podi}i svijest o dokazima koji podupiru upotrebu dopune kon-
vencionalnoj terapiji u skrbi dijabetesa.
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